4.6 Article

89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas

期刊

ACS OMEGA
卷 8, 期 25, 页码 22486-22495

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsomega.3c00624

关键词

-

向作者/读者索取更多资源

Multiple myeloma (MM) and lymphomas are hematological malignancies with high unmet clinical needs. In this study, a novel immunoPET tracer, 89Zr-DFO-isatuximab, was developed for targeted imaging of CD38, an excellent biomarker for MM and certain lymphomas. In vitro validation demonstrated its high binding affinity and specificity. PET imaging further confirmed its effectiveness in delineating tumor burden in MM and Burkitt's lymphoma models. The potential of 89Zr-DFO-isatuximab as an alternative to 89Zr-DFO-daratumumab holds great clinical relevance.
Multiple myeloma (MM) is the second most prevalent hematological malignancy. It remains incurable despite the availability of novel therapeutic approaches, marking an urgent need for new agents for noninvasive targeted imaging of MM lesions. CD38 has proven to be an excellent biomarker due to its high expression in aberrant lymphoid and myeloid cells relative to normal cell populations. Using isatuximab (Sanofi), the latest FDA-approved CD38-targeting antibody, we have developed Zirconium-89(89Zr)-labeled isatuximab as a novel immunoPET tracer for the in vivo delineation of MM and evaluated the extension of its applicability to lymphomas. In vitro studies validated the high binding affinity and specificity of 89Zr-DFO-isatuximab for CD38. PET imaging demonstrated the high performance of 89Zr-DFO-isatuximab as a targeted imaging agent to delineate tumor burden in disseminated models of MM and Burkitt's lymphoma. Ex vivo biodistribution studies confirmed that high accumulations of the tracer in bone marrow and bone skeleton correspond to specific disease lesions as they are reduced to background in blocking and healthy controls. This work demonstrates the promise of 89Zr-DFO-isatuximab as an immunoPET tracer for CD38-targeted imaging of MM and certain lymphomas. More importantly, its potential as an alternative to 89Zr-DFO-daratumumab holds great clinical relevance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据